Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01060345 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01060345 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 20 participants.
The verdict
NCT01060345, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to find molecular signs (biomarkers) to better understand the role of green tea as an anti-cancer and anti-inflammation agent in women with newly-diagnosed ductal carcinoma in situ (DCIS).
Interventions
- DRUG Polyphenon E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-05 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01060345
The ClinicalTrials.gov registry entry for NCT01060345 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Polyphenon E is the first listed.
NCT01060345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01060345 about?
NCT01060345 is a clinical study titled "A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ". The purpose of this study is to find molecular signs (biomarkers) to better understand the role of green tea as an anti-cancer and anti-inflammation agent in women with newly-diagnosed ductal carcinoma in situ (DCIS).
What is the current status of trial NCT01060345?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2010-05. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01060345?
The interventions under investigation include: Polyphenon E (DRUG).
Who is sponsoring clinical trial NCT01060345?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.